ADMA Biologics (NASDAQ:ADMA) Shares Gap Up - Here's Why

Key Points

• Culper short report
• ADMA issued a formal rebuttal calling the allegations “unsubstantiated,” and the shares gapped up premarket (from $8.29 to $9.47) on heavy volume and an unusual surge in call buying (~22,398 contracts, ~848% above average), suggesting speculative/hedged buying that could create short‑term upside.
• On the fundamentals side, ADMA recently reported Q4 EPS of $0.20 (in line) and revenue of ~$139M (up 18.4% YoY), has low leverage (debt/equity 0.16 and strong liquidity ratios), and a consensus analyst price target of $32.00 despite mixed ratings.

ADMA Biologics Inc (NASDAQ:ADMA - Get Free Report)'s share price gapped up before the market opened on Friday . The stock had previously closed at $8.29, but opened at $9.47. ADMA Biologics shares last traded at $9.2850, with a volume of 7,779,818 shares.

Key ADMA Biologics News

Here are the key news stories impacting ADMA Biologics this week:

• Positive Sentiment: ADMA published a formal rebuttal calling the Culper allegations “unsubstantiated, misleading and inaccurate,” emphasizing ASCENIV’s role as a late‑line therapy and disputing the short‑seller’s competitive characterization. ADMA Biologics Issues Statement Refuting Unsubstantiated, Misleading and Inaccurate Allegations by Culper Research
• Positive Sentiment: Unusual options activity: traders bought ~22,398 call contracts (an ~848% increase vs. average), indicating speculative/hedged buying that can create short‑term upside pressure.
• Neutral Sentiment: High volume trading and elevated liquidity: trading volume and option flow are far above average, increasing intraday volatility but not resolving the core fundamental dispute.
• Negative Sentiment: The Culper short report alleged channel stuffing and overstated growth; that report is the catalyst for the selloff and investor concern. INVESTOR ALERT: Investigation of ADMA Biologics Inc. (ADMA) Announced by Holzer & Holzer, LLC
• Negative Sentiment: Multiple law firms have opened shareholder securities‑fraud investigations and issued investor alerts, increasing legal risk and the chance of costly litigation or restatements. Securities Fraud Investigation Into ADMA Biologics, Inc. (ADMA) Announced – Glancy Prongay Wolke & Rotter LLP
• Negative Sentiment: Analyst pressure: Cantor Fitzgerald downgraded ADMA following the short report, which can amplify selling and reduce demand from institutional holders. Cantor Fitzgerald downgrades ADMA Biologics (ADMA)
• Negative Sentiment: Market impact: reports state the stock slid sharply (reportedly ~29% at one point) after the allegations, and the resulting sell pressure and investigations remain the primary downside drivers. $ADMA Shareholders: ADMA Biologics Hit with Securities Fraud Investigation After Stock Slides 29% Amid Channel Stuffing Claims

Wall Street Analyst Weigh In

A number of analysts have recently weighed in on the company. Weiss Ratings reiterated a "hold (c)" rating on shares of ADMA Biologics in a research report on Tuesday, December 23rd. Cantor Fitzgerald reaffirmed a "neutral" rating on shares of ADMA Biologics in a research note on Thursday. Wall Street Zen upgraded shares of ADMA Biologics from a "hold" rating to a "buy" rating in a research note on Saturday, February 28th. Finally, Zacks Research raised shares of ADMA Biologics from a "hold" rating to a "strong-buy" rating in a report on Monday, March 2nd. Two investment analysts have rated the stock with a Strong Buy rating and two have assigned a Hold rating to the stock. According to MarketBeat.com, the stock currently has an average rating of "Buy" and a consensus price target of $32.00.

ADMA Biologics Price Performance

The company has a debt-to-equity ratio of 0.16, a quick ratio of 3.74 and a current ratio of 6.71. The company has a market cap of $2.27 billion, a price-to-earnings ratio of 16.03 and a beta of 0.51. The business has a fifty day moving average price of $15.76 and a 200 day moving average price of $16.47.

ADMA Biologics (NASDAQ:ADMA - Get Free Report) last released its quarterly earnings data on Wednesday, February 25th. The biotechnology company reported $0.20 earnings per share for the quarter, meeting the consensus estimate of $0.20. The business had revenue of $139.16 million for the quarter, compared to analyst estimates of $139.80 million. ADMA Biologics had a return on equity of 37.52% and a net margin of 28.80%.ADMA Biologics's revenue was up 18.4% compared to the same quarter last year. During the same period last year, the firm posted $0.46 earnings per share. As a group, research analysts anticipate that ADMA Biologics Inc will post 0.51 earnings per share for the current year.

Insider Buying and Selling

In related news, Director Steve Elms purchased 7,000 shares of the stock in a transaction dated Thursday, March 5th. The stock was bought at an average cost of $15.67 per share, for a total transaction of $109,690.00. Following the completion of the acquisition, the director owned 2,038,730 shares of the company's stock, valued at approximately $31,946,899.10. This represents a 0.34% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, COO Kaitlin M. Kestenberg-Messina sold 10,096 shares of the business's stock in a transaction on Monday, March 9th. The stock was sold at an average price of $15.63, for a total value of $157,800.48. Following the sale, the chief operating officer owned 466,600 shares in the company, valued at $7,292,958. This represents a 2.12% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 3.50% of the stock is owned by corporate insiders.

Institutional Trading of ADMA Biologics

Hedge funds and other institutional investors have recently made changes to their positions in the company. Salomon & Ludwin LLC acquired a new position in shares of ADMA Biologics in the third quarter valued at approximately $25,000. Rothschild Investment LLC grew its holdings in ADMA Biologics by 373.8% during the 3rd quarter. Rothschild Investment LLC now owns 1,895 shares of the biotechnology company's stock worth $28,000 after acquiring an additional 1,495 shares during the last quarter. Summit Securities Group LLC acquired a new position in ADMA Biologics in the 4th quarter valued at approximately $29,000. Clearstead Advisors LLC increased its position in ADMA Biologics by 55.7% in the 3rd quarter. Clearstead Advisors LLC now owns 2,222 shares of the biotechnology company's stock valued at $33,000 after acquiring an additional 795 shares during the period. Finally, iSAM Funds UK Ltd bought a new position in shares of ADMA Biologics during the third quarter valued at $34,000. 75.68% of the stock is currently owned by institutional investors.

About ADMA Biologics

ADMA Biologics, Inc is a biopharmaceutical company headquartered in Ramsey, New Jersey, that focuses on the development, manufacturing and commercialization of specialty plasma-derived biologics for the treatment of primary immunodeficiency and infectious diseases. Leveraging an integrated model that spans plasma collection, fractionation, formulation and fill-finish operations, ADMA Biologics aims to address unmet needs in immune-compromised and high-risk patient populations.

The company's marketed product portfolio includes BIVIGAM, a human immunoglobulin intravenous (IGIV) therapy approved by the U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.